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Background: Patients with low cardiovascular disease (CVD) risk potentially use preventive 
cardiovascular medication unnecessarily. Our aim was to identify various viewpoints and 
beliefs concerning the preventive CVD management of patients with low CVD risk using pre-
ventive cardiovascular medication. Furthermore, we investigated whether certain viewpoints 
were related to a preference for deprescription or the continuation of preventive cardiovascular 
medication.
Methods: In 2015, we purposively sampled patients from the intervention arm of the Evaluating 
Cessation of STatins and Antihypertensive Treatment In primary Care (ECSTATIC) trial in 
the Netherlands for this study. Participants made Q-sorts by ranking 43 statements concerning 
preventive CVD management from “totally disagree” to “totally agree”. These Q-sorts were 
analyzed using PQMethod 2.35 software. A varimax procedure presented the distinguishing 
viewpoints that were favored by our participants. We used group discussion quotations to 
underline our findings. For validation purposes, we asked participants how well each viewpoint 
fitted them.
Results: Of 291 invited patients, 33 participated. Thirty-one Q-sorts were analyzed. The 
following three viewpoints were found: 1) a controlling viewpoint, in which patients held 
the belief that monitoring blood pressure and cholesterol levels is important (n=13, of which 
seven had their medication deprescribed and six continued their medication); 2) an autonomous 
viewpoint, in which patients showed a dislike of medication (n=8, of which seven had their 
medication deprescribed and one had it continued); and 3) an afraid viewpoint, in which patients 
were fearful of developing CVD (n=8, of which two had their medication deprescribed and six 
had it continued). Seventy-four percent of the participants believed that the viewpoint to which 
they were assigned was a good fit.
Conclusion: Three well-discriminating viewpoints about preventive CVD management were 
determined. Knowing and recognizing these viewpoints is effective for general practitioners 
when discussing the deprescribing of preventive cardiovascular medications with patients and 
may be used to promote implementation of deprescription.
Keywords: general practice, preventive medicine, cardiovascular diseases, antihypertensive 
agents, anticholesteremic agents, inappropriate prescribing
Introduction
According to the guidelines of many countries, patients with predicted low cardiovas-
cular disease (CVD) risk do not require medication to prevent CVD.1–6 Nonetheless, 
preventive cardiovascular medication is often prescribed and used by patients with 
lower levels of predicted CVD risk than the actual guideline thresholds, because 
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recommendations for drug initiation have been revised after 
treatment has been started.7,8 Deprescribing these potentially 
inappropriate medications can reduce unnecessary adverse 
reactions in patients and undue medical costs. In an earlier 
study, we identified the barriers and enablers that patients 
and general practitioners (GPs) mention during consultations 
in which the deprescribing of preventive cardiovascular 
medication is discussed.9 Patients expressed doubts about 
the appropriateness of their medication and seemed to rely 
on the information and expertise of their GP in determining 
whether deprescribing was justified. This finding was also 
observed in other studies.10–12 Furthermore, a general dislike 
of medication and knowing that follow-up care was available 
and medication could be restarted are known to be enablers 
of deprescribing.9,13 Patients’ expectations of the long-term 
medications they use play a role in their willingness to have 
their preventive medication deprescribed. Dohnhammar 
et al14 reported that patients use medication to care for them-
selves above and beyond lifestyle changes alone and that they 
tend to overestimate the risk-lowering effects of preventive 
medication. Furthermore, patients and doctors balance risks 
and benefits of medication in a different way. For example, 
benefits in the short term are identified as more important to 
patients compared with doctors.14 Patients’ views on depre-
scribing their medication can thus be different than their 
physicians’ views, but patient viewpoints could influence the 
implementation of preventive CVD management. Therefore, 
our objective was to identify various viewpoints and beliefs in 
patients with low CVD risk using preventive cardiovascular 
medication concerning preventive CVD management. Hence, 
we performed a Q-methodological study in patients with low 
CVD risk who had discussed deprescribing their preventive 
cardiovascular medication with their GP.
Methods
Q-methodology
To investigate the viewpoints of patients with low CVD 
risk concerning their preventive CVD management, a 
Q-methodological study was conducted. Q-methodology 
combines the strengths of both qualitative and quantitative 
methods, which enables the conversion of subjective perspec-
tives into an objective outcome.15 Although Q-methodology 
does not claim to identify viewpoints that are consistent 
within individuals across time, it is expected that viewpoints 
should show some degree of consistency over time. Hence, 
for the possible future implementation of a deprescribing 
policy, Q-methodology seems to be an appropriate way 
to investigate whether certain viewpoints are related to 
a preference for deprescription or for the continuation of 
preventive cardiovascular medication.15 In contrast to quali-
tative analyses, Q-methodology focuses on groups instead 
of individuals, and therefore on the variety of viewpoints 
instead of on the viewpoint of the majority. It focuses on 
similarities and differences in a study population, resulting 
in various viewpoints or patterns of thought that specify a 
given population. The method consists of the following four 
steps, which we will further describe: 1) the determination 
of the concourse and generation of a Q-set, 2) the generation 
of a P-set (study population), 3) performing the Q-sorts, and 
4) factor analysis and interpretation.
Q-set
The Q-set consisted of statements representing the con-
course, the full range of contributions in the qualitative 
debate, on preventive CVD management. Statements were 
based on the literature,10,11,13 expert opinion and data from 
our previous study concerning the barriers and enablers that 
patients mention during deprescribing consultations with 
their GPs.9 Researchers (CHL, NLB, and RKEP) formulated 
44 statements to cover the concourse. After testing the Q-set 
with four patients to determine the clarity of the statements 
and their sufficiency in displaying different viewpoints, 
a final Q-set of 43 statements was established. These were 
randomly numbered and printed on cards.
P-set
The study population was purposively sampled from the 
Evaluating Cessation of STatins and Antihypertensive Treat-
ment In primary Care (ECSTATIC) trial (NTR3493). In the 
ECSTATIC trial (a randomized controlled trial that started 
in 2012, with follow-up ending in November 2015), we 
evaluated whether it is cost-effective and safe to deprescribe 
antihypertensive and lipid-lowering drugs in primary care 
patients for whom medication is not recommended accord-
ing to the current Dutch guideline on Cardiovascular Risk 
Management (Box 1). Participants from the intervention 
practices were offered a consultation with their GP to dis-
cuss whether to deprescribe their preventive cardiovascular 
medication.
We sent written invitations to all patients from the inter-
vention practices of the ECSTATIC trial (n=291) living in 
and around the cities of Leiden and Alphen aan den Rijn. 
Based on the preferred dates, we organized five sessions: 
three with patients who stopped their preventive cardio-
vascular medication 2 years ago and who still received no 
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Understanding deprescribing of preventive cardiovascular medication
group) and two with patients who had continued or restarted 
preventive cardiovascular medication or who had lowered 
their dose of their medication during the 2-year follow-up 
period (the continuation group).
Q-sorts
The sorting board that patients used to rank statements fol-
lowed the Q-convention of a “forced normal distribution” 
(Figure S1).
Individual patients were given a pile of 43 statement 
cards and made piles containing statements with which they 
agreed, disagreed, or were neutral (no opinion or irrelevant). 
Next, each patient ordered the statements. On the extreme 
left, they placed the statements they disagreed with most. 
Next to those statements, they placed statements they 
disagreed with to a lesser extent, and so on. They did the same 
with the statements they agreed with most, except that these 
were placed on the right end of the sorting board. Finally, 
neutral statements were ordered and placed on the empty 
spots of the sorting board.
Factor analysis and interpretation
We analyzed the Q-sorts with PQMethod 2.35 software 
and used the varimax procedure to reveal the range of 
viewpoints that were favored by our study population.15 
An algorithm was used to calculate how high the corre-
lation coefficient must be and how much the correlation 
coefficient of the factor must differ from the correlation 
coefficient of the other factors to state that a person loads 
on to that specific factor. The patients loading on a specific 
factor are the patients with the most representative Q-sorts 
for this factor.16 Only the Q-sorts of patients loading on 
a specific factor were used for subsequent calculations. 
For each specific factor, an “ideal Q-sort” was created, 
showing how a hypothetical patient loading 100% on the 
factor would have ranked the statements. To interpret and 
name the factor, we used the Z-scores of the statements in 
these ideal Q-sorts, as well as the presented distinguish-
ing and consensus statements of the factors. We reported 
statements distinguishing between any pair of factors with 
a P-value ,0.01 (distinguishing statements) and state-
ments not distinguishing between any pair of factors with 
a P-value .0.01 (consensus statements).
After patients ranked their statements on the sorting 
board and their informed consent was audiotaped, we asked 
them to reflect on their rank ordering. Their reflections 
and the following group discussions were audiotaped and 
used for the further interpretation of the factors. Due to a 
technical problem in one of the sessions, we had to leave 
one group discussion from the desprescription group out of 
our analysis.
We identified the distribution of patients from the 
deprescription and continuation group across the factors. 
A chi-square test was used to examine the significance of 
this distribution.
To validate the factors that resulted from the 
Q-methodology, we made factor descriptions highlighting 
the important distinguishing characteristics of the differ-
ent factors. This validation questionnaire was sent to the 
patients. We asked them how well each factor description 
fitted them, using a five-point Likert scale ranging from 
“totally not” to “very well”. The study was approved by 
the Medical Ethics Committee of the Leiden University 
Medical Center.
Results
Of the 291 invited patients, 33 were willing to participate. 
There were no statistically significant differences between the 
respondents and nonrespondents with regard to age or gender. 
Two patients were excluded from the analysis of the Q-sorts 
Box 1 ecsTATic trial
The ecsTATic trial evaluates whether it is cost-effective and safe to deprescribe antihypertensive and lipid-lowering drugs in primary care patients 
to whom medication is not recommended according to the current Dutch guideline on cardiovascular risk Management. Patients without cVD 
were included in the ecsTATic trial when having low cVD risk and using antihypertensive and/or lipid-lowering drugs. gPs in the intervention 
practices received a training providing information about this guideline and its differences with respect to the former guideline. in preparation of 
the deprescribing consultations, there were presented cases of fictional low CVD risk patients and they discussed these patients’ suitability to have 
their medication deprescribed.
gPs participating in the trial sent a written invitation to their patients without cVD, using potentially inappropriate antihypertensive and/or 
lipid-lowering drugs. After obtaining the informed consent, the researchers determined eligibility on the basis of the patients’ pretreatment 10-year 
risk of morbidity and mortality of cVD, using the scOre risk function as well as their (possible) additional risk increasing factors (positive family 
history for cVD, obesity, decreased kidney function, and sedentary lifestyle) (1). When, based on the combination of the risk score and additional 
risk increasing factors for cVD, medication was not recommended according to the current guideline cardiovascular risk Management, patients 
were considered eligible for inclusion and were advised to make an appointment for a deprescribing consultation with their gP.
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(incomplete Q-sort and language barrier). The characteristics 
of the patients who performed the Q-sort (n=31) and of those 
who participated in the group discussions (n=28) are shown 
in Table 1.
Table 2 shows the consensus and distinguishing state-
ments in the Q-set. All patients had the idea that they could 
do something to reduce their CVD risk, even if CVD ran in 
their families (statement 5). Patients placed importance on 
a GP with good communication skills who explained their 
treatment options clearly (statement 12). 
I feel that she shows interest in me as a patient and I always 
get a good advice, that is medically substantiated. [60-year-
old female in the continuation group]
Another patient said:
When I go there [to the GP] I feel heard, and he takes time 
to explain things, and when he explains things to me, in 
the end, most of the time I don’t even need medication, 
so, that’s just really important to me. [66-year-old woman 
in the continuation group]
They did not feel medications were unnatural (statement 6), 
and all patients regarded hypertension management as one 
of the GPs’ job responsibilities (statement 7).
In addition, three distinguishable factors emerged from 
the Q-sorts (Table 2), explaining 52% of the variance 
in our data. The patients from the description and con-
tinuation groups were unequally distributed across these 
factors (P=0.04).
Factor 1: controlling (n=13; seven from 
the deprescription group and six from 
the continuation group)
Patients loading on this factor placed great importance on 
the periodical monitoring of blood pressure and cholesterol 
levels by their GP, whether they were using medication or 
not (statement 19). During group discussions, these patients 
expressed dissatisfaction with their GP on this point:
For years, I’ve been getting these repeated prescriptions, 
but no one [in the general practice] has ever said to me: let’s 
measure your blood pressure […] well, I think that is regret-
table. [56-year-old woman in the continuation group]
If CVD ran in their families, they were more inclined to start 
using medication (statement 35):
I think that when it [blood pressure] is always really high 
and it is familial, you are more inclined to just continue tak-
ing that medication because in that case, it is different than 
just having [high blood pressure], well, yes. [66-year-old 
woman in the continuation group]
For patients loading on this factor, maintaining a healthy 
lifestyle was something obvious. 
Being aware of what you eat, a bit of exercising, just the 
normal things. [62-year-old woman in the deprescription 
group]
Hence, they felt that nobody should smoke (statement 34). 
In addition, they easily maintained a healthy lifestyle, and 
they never sought professional help to live (even) healthier 
(statements 23 and 36, respectively).
Factor 2: autonomous (n=8; seven from 
the deprescription group and one from 
the continuation group)
These patients would really appreciate living a long life 
without using medication, and they did not feel physically 
better when using medication (statements 33 and 21, 
respectively). Hence, they disagreed that using more 
and more medications comes along with growing old 
(statement 15). They disliked medication: 
Throw it [medication] in the dustbin, that crap. [50-year-old 
woman in the deprescription group]
Furthermore, they were interested in the way that the 
medication worked, and they knew exactly why they did 
Table 1 characteristics of the patients who performed the Q-sort and of the patients who participated in the group discussions
Characteristics Q-sort patients  
(n=31)
Group discussion patients (n=28), 
the Netherlands, February and March 2015
Male, n (%) 9 (29.0) 9 (32.1)
Age, years, mean (sD) 57.1 (6.8) 57.7 (6.8)
Using/used antihypertensive medication, n (%) 18 (58.1) 16 (57.1)
Using/used lipid-lowering drugs, n (%) 7 (22.6) 7 (25.0)
Using/used both medications, n (%) 6 (19.4) 5 (17.9)
Deprescription group, n (%) 17 (54.8) 13 (46.4)
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Understanding deprescribing of preventive cardiovascular medication
Table 2 consensus and distinguishing statements in the Q-set and the values of the ideal Q-sort per factor










 1. A healthy lifestyle is important to keep my cVD risk as low as possible* 3 2 4
 2. My individual cVD risk can change over time* 1 1 0
 3. My own experiences and the ones from people around me were the most 
important in my decision whether or not to deprescribe the medication for my 
blood pressure/cholesterol level*
0 -1 -1
 4. Medications for blood pressure/cholesterol level are very safe in comparison to 
other kinds of medications*
-1 -1 0
 5. if cVD runs in your family, you can do very little to prevent developing cVD 
yourself**
-2 -2 -2
 6. Medications are unnatural** 0 0 -1
 7. i feel a bit ashamed when i come to my gP for my blood pressure; he does not 
have much time and should help patient who are really ill**
-2 -3 -4
 8. i fear(ed) for side effects of blood pressure/cholesterol level lowering medication* -1 0 -1
 9. i would rather use medication than change my lifestyle to reduce my cVD risk* -4 -4 -3
 10. i am afraid that long-term use of medication for my blood pressure/cholesterol level 
will have negative effects on me*
0 0 1
 11. it is important that i can communicate well with my gP* 2 3 2
 12. it is important that my gP clearly explains why i need a certain treatment, what the 
options are, and how the medication works**
4 3 3
Distinguishing statements
 13. i understand well why i do or do not use medication for high blood pressure/
cholesterol level
2 4*** 1
 14. i feel relieved when my cholesterol level is ok when it is checked 1 1 4***
 15. Using more and more medications just accompanies getting older -2 -3 0***
 16. i know which food is healthy and will help me lowering my cholesterol level 1 4*** 1
 17. if i experience less stressful events my blood pressure will be lower as well 2 2 0***
 18. i am interested in the mechanisms of different medications for high blood pressure 0 1 -1***
 19. it is important that my gP keeps monitoring my blood pressure, whether i use 
medication or not
4*** 0*** 2***
 20. it is scary to walk around having a high blood pressure 3*** -2*** 2***
 21. i feel physically better when i use medication for my blood pressure or 
cholesterol level
0 -4*** 0
 22. i do not make decisions concerning medication use alone, but together with my 
partner/family/friends
-2 0 -2***
 23. it is hard to maintain a healthy lifestyle -3*** 1 2
 24. i would rather increase the dose of one medication than use a combination of two 
medications in a lower dose
0 -1 -2***
 25. I always read the information leaflet before I start using medication 1 1 3***
 26. i am afraid of developing a heart attack or stroke -1 0 2***
 27. Whether medication is reimbursed plays a role in my decision to use them or not -3 -2*** -4
 28. Doctors prescribe medication too easily -2 0*** -1
 29. Using medication for my high blood pressure gives me a feeling of control 0*** -1 -2
 30. if i have a low risk of developing cVD i do not have to use medication to prevent it 1 2*** 0
 31. it is just a small effort to take medication 2 0*** 1
 32. i trust my gP in making the right decisions for me 1 -1*** 0
 33. My wish is to become a 100-year old without using medication 0*** 3*** -1***
 34. nobody should smoke 3*** 1 1
 35. if cVD runs in my family i am more inclined to take medication 2 -1*** 1
 36. i have searched for help in order to achieve a healthier lifestyle (eg, help to stop 
smoking, dietary advice, advice of a sports instructor)
-3*** 0*** 3***
Remainder statements
 37. Medications that lower blood pressure or cholesterol level are expensive -1 -1 -2
 38. if my partner or good friend/colleague would advise me to continue my medication 
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or did not use medication to lower their blood pressure or 
cholesterol levels (statements 18 and 13, respectively).
I Googled like crazy, especially when it was suggested to 
start medication, why is that necessary, what is the matter, 
what are the effects [of the medication], I did it [Google] 
far less when stopping it [the medication] was discussed. 
[54-year-old man in the deprescription group]
Having a high blood pressure did not scare them, whereas 
having a low cardiovascular risk was a reason for 
them to deprescribe preventive cardiovascular medica-
tion, even if CVD ran in their families (statements 20 
and 35, respectively). In contrast to the other factors, 
patients loading on this factor did not have that much 
confidence in the decisions their GP made for them 
(statement 32). These patients decided for themselves 
whether they would or would not use medication.
It was me [who made the decision to deprescribe]. The GP 
then checked whether it [deprescribing] was justified, and 
he said it was justified. Then I said, well, in that case I’ll 
stop [the medication]. [64-year-old woman in the depre-
scription group]
Factor 3: afraid (n=8; two from the 
deprescription group and six from the 
continuation group)
Patients loading on this factor felt relieved when their blood 
pressure or cholesterol test result was in order and were afraid 
to develop a stroke or heart attack (statements 14 and 26). 
I’m scared I’ll get a heart attack or a stroke, although I use 
medication, I will always have that fear. [68-year-old 
woman in the continuation group]
In contrast to the other factors, these patients did not hesi-
tate to turn to professionals to help improve their lifestyle 
(statement 36). However, it was hard for them to change and 
maintain a healthy lifestyle (statement 23). 
There is nothing as hard as changing your lifestyle. 
[53-year-old man in the continuation group]
They were afraid of the negative effects of the long-
term use of antihypertensive and lipid-lowering drugs 
(statement 10).
You take them [medications] because you think they will 
help you […] what would be the negative effect in the long 
term, concerning my cholesterol pills that is not that clear 
to me. [47-year-old man in the deprescription group]
Furthermore, they always read the information leaf-
let of their medications (statement 25).
Table 3 Patients’ (n=31) reports on whether or not the three 
distinguishable factors that emerged from the Q-sorts fitteda them
Patients Loading 
on factor 1 
(n=13)
Loading 
on factor 2 
(n=8)
Loading 







Fitting factor 1 10 3 2 1
Fitting factor 2 3 6 2 1
Fitting factor 3 1 0 4 0
Fitting just one factor 9 5 4 0
Fitting two factors 1 2 2 1
Fitting three factors 1 0 0 0
Not fitting any factor 2 0 1 0
nonrespondents 0 1 1 1
Notes: aWell or very well. Bold data show the concordance between the factor-
loading according to analysis of the Q-sorts and the factor-fitting according to the 
patient.
Table 2 (Continued)









 39. i would appreciate it more if my gP decides for me whether or not i should use 
medication than i would appreciate deciding that myself
-1 -2 -1
 40. if my gP explains things to me, i am able to retell it when i am home 1 2 0
 41. Use of medications should be prevented or restricted as much as possible 0 2 1
 42. i would want to reduce my cVD risk with alternative medicine such as homeopathy 
or acupuncture
-1 1 0
 43. if i can stop my medication for high blood pressure/cholesterol level, i will continue 
until the package is empty, otherwise it would be a waste
-4 -3 -3
Notes: *consensus statement that does not distinguish between any pair of factors with a P-value .0.01. **consensus statement that does not distinguish between any 
pair of factors with a P-value .0.05. ***Distinguishing statement (the marker is placed at the Q-sort value of the factor for which the statement is a distinguishing statement 
between any pair of factors with a P-value ,0.01).
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Validation questionnaire
The validation questionnaire was sent to 31 patients. A total 
of 29 patients responded. Of these, 27 loaded onto one of 
three factors (Table 3). In 74% (20/27) of the cases, patients 
self-selected the factor they loaded on, indicating that this 
factor fitted them “well” or very well. Seven patients reported 
that more than one factor description contained elements 
matching their ideas.
Discussion
With our Q-methodology study, we aimed 1) to identify 
the viewpoints of patients with low CVD risk concerning 
preventive CVD management and 2) to investigate whether 
certain viewpoints were related to a preference for either 
the deprescription or continuation of preventive cardiovas-
cular medication. We found the following three viewpoints: 
1) controlling, 2) autonomous, and 3) afraid viewpoints. 
Patients who had their preventive cardiovascular medica-
tion deprescribed were differentially distributed across these 
viewpoints relative to patients who continued their medi-
cation. Most of the patients loading onto the autonomous 
viewpoint had their medication deprescribed, and most of the 
patients loading onto the afraid viewpoint had it continued. 
Several group discussion statements reinforced the findings 
of our Q-methodology, and in 74% of the cases, patients self-
selected the factor they loaded on as fitting them well.
strengths and limitations
Using Q-methodology and postsort group discussions led to 
profound understanding of the factor arrays. The inclusion of 
patients who had deprescribed their medication and patients 
who had continued their medication ensured that different 
viewpoints were represented in our data. The participation 
grade of the study was fairly low, probably because of the 
fixed dates we offered for our sessions, combined with our 
working class population. However, as discussed by Watts 
and Stenner,15 our sample size was considered sufficiently 
large for a Q-methodological study to reveal some of the 
main viewpoints that were favored by our specific study 
population. Moreover, our study population was similar to the 
nonrespondents in terms of age and gender. Because of their 
participation in the ECSTATIC trial, it is possible that our 
study population had more negative views toward preventive 
cardiovascular medication use than patients generally have. 
The outcomes might therefore not be generalizable in that 
respect. The goal of this Q-methodological study, however, 
was to identify different patterns of thought in our specific 
population. One of the strengths of this study is that the study 
population had previously discussed deprescribing with their 
GPs. We believe that this ensured that their views and opin-
ions were well thought-out, resulting in balanced outcomes. 
Furthermore, it enabled us to link the patients who had 
deprescribed or continued their medication with the factors 
we found, revealing a more defined image of the viewpoints 
of patients loading on these factors. This information may be 
helpful for implementation purposes. In addition, by asking 
all patients how well each factor fitted them, we were able 
to show that our factor description indeed represented the 
viewpoints of the patients within the study population.
comparison with existing literature
Results from our Q-methodology overlap with the outcomes 
of several other studies. For example, similar observations 
had been made previously regarding the importance patients 
place on monitoring blood pressure and cholesterol10,13 
(controlling and afraid), the role of stress as a cause of 
hypertension17 (controlling), the search for aides in chang-
ing one’s lifestyle to reduce the effects of modifiable factors 
that influence blood pressure and cholesterol,10 and the fear 
of developing CVD17 (afraid). It is known that a dislike of 
medication and a lack of confidence in its prescriber are 
enablers of deprescribing.13,18 These characteristics were 
shared by the patients loading on the autonomous viewpoint, 
and these patients were indeed more likely to have their medi-
cation deprescribed. However, the fear of side effects is also 
known as an enabler of deprescribing,13 but patients loading 
onto the afraid viewpoint were more likely to continue their 
medication. This is likely because they feared CVD even 
more than the side effects, or because they were not able to 
change their lifestyle.14
Morecroft et al10 found that about half of the patients 
with hypertension believed that appropriate antihyperten-
sive treatment involved leaving medical decisions to their 
GPs. Interestingly, all patients in our study population 
appreciated being involved in the general decision-making 
process. Considering the comparable age groups of both 
study populations, this may represent changing medical 
attitudes or cultural differences between patients in the UK 
and the Netherlands.
Practice implications
Knowing which views and thoughts patients have concerning 
preventive CVD management may be helpful for GPs when 
discussing this topic with a patient in daily practice. Further-
more, when planning to implement a deprescription strategy 
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seems appropriate to start implementation in patients who 
have an autonomous viewpoint because deprescribing is most 
likely to be successful in this group of patients. We believe 
that this approach to start implementation will not be very 
time-consuming because most GPs can clearly identify the 
patients who fit this profile.
Conclusion
The three well-discriminating viewpoints concerning 
preventive CVD management that emerged from our 
Q-methodological study (controlling, autonomous, and 
afraid) can be used for implementation and communication 
purposes in deprescribing. Table 4 shows some suggestions 
on how to detect patients with certain viewpoints and how 
to optimally communicate with them.
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